应用复方氨基酸注射液(20AA)治疗晚期妊娠重度子痫前期的临床研究

Clinical study on application of compound amino acid-20AA for the treatment of severe preeclampsia in late pregnancy

目的:探讨复方氨基酸注射液(20AA)在改善重度子痫前期孕妇营养状态和提高新生儿预后中的价值。方法:回顾性分析妊娠晚期重度子痫前期孕妇的治疗方案,对照组80例接受常规治疗,治疗组48例加用复方氨基酸注射液(20AA)、38例加用白蛋白治疗,比较各组血清蛋白水平和新生儿出生体重、脐动脉血气pH值。结果:复方氨基酸注射液(20AA)治疗组内治疗前后血清蛋白各项指标下降差异无统计学意义(P>0.05);应用复方氨基酸注射液(20AA)组和白蛋白组治疗后各项血清蛋白指标均明显高于对照组,差异有统计学意义(P<0.05);复方氨基酸注射液(20AA)与白蛋白治疗组间比较,治疗后各血清蛋白指标间差异无统计学意义(P>0.05);应用复方氨基酸注射液(20AA)新生儿脐动脉血pH值明显高于白蛋白组和对照组,差异有统计学意义(P<0.01);应用复方氨基酸注射液(20AA)后新生儿出生体重有上升趋势,但各组间差异无统计学意义(P>0.05)。结论:复方氨基酸注射液(20AA)可以减轻和纠正晚期妊娠重度子痫前期低蛋白血症,提高围产儿预后。

Objective： To investigate the effect of compound amino acid -20AA on improving the nutritional status and neonatal prognosis in late pregnancy with severe preeclampsia. Methods： Treatment of severe preeclampsia pregnant women in late pregnancy was ret- rospectively analyzed. 80 cases in the control group received routine treatment, 48 cases were treated with compound amino acid 20 - AA, 38 cases were treated with albumin. Serum protein levels, neonatal birth weight, umbilical artery PH value were compared. Results： There was no significant difference in decreased serum protein （P 〉 0. 05） before and after treatment with compound amino acid 20 - AA. Serum pro- tein were significantly higher than that of the control group （ P 〈 0. 05 ） after treatment with compound amino acid 20 - AA and albumin, there was no significant difference in serum protein between compound amino acid 20 - AA and albumin in the treatment groups （ P 〉 0. 05 ）. The umbilical artery pH value was significantly higher than that of albumin group and control group （P 〈 0. 01 ） after application of compound amino acid 20 - AA. The neonatal birth weight had been increased after application of compound amino acid 20 - AA, but there was no sig- nificant difference between groups （ P 〉 0.05 ） . Conclusion： Compound amino acid 20 - AA can reduce and correct hypoproteinemia of se- vere preeclampsia pregnant women in late pregnancy and can improve the perinatal prognosis.